Ullamari Pesonen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7163074/publications.pdf

Version: 2024-02-01

159525 189801 2,797 81 30 50 citations h-index g-index papers 82 82 82 2955 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Association of a leucine(7)-to-proline(7) polymorphism in the signal peptide of neuropeptide Y with high serum cholesterol and LDL cholesterol levels. Nature Medicine, 1998, 4, 1434-1437.	15.2	214
2	Altered intracellular processing and release of neuropeptide Y due to leucine 7 to proline 7 polymorphism in the signal peptide of preproneuropeptide Y in humans $<$ sup $>$ 1 $<$ /sup $>$. FASEB Journal, 2001, 15, 1242-1244.	0.2	133
3	An insertion/deletion polymorphism in the $\hat{l}\pm 2b$ -adrenergic receptor gene is a novel genetic risk factor for acute coronary events. Journal of the American College of Cardiology, 2001, 37, 1516-1522.	1.2	110
4	C957T polymorphism of the human dopamine D2 receptor gene predicts extrastriatal dopamine receptor availability in vivo. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 630-636.	2.5	106
5	Identification of a Three-Amino Acid Deletion in thel± 2B-Adrenergic Receptor That Is Associated with Reduced Basal Metabolic Rate in Obese Subjects. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 2429-2433.	1.8	103
6	Leucine7 to proline7 polymorphism in the preproneuropeptide Y is associated with the progression of carotid atherosclerosis, blood pressure and serum lipids in Finnish men. Atherosclerosis, 2001, 159, 145-151.	0.4	101
7	Influence of hydroxychloroquine on the bioavailability of oral metoprolol. British Journal of Clinical Pharmacology, 2000, 49, 549-554.	1.1	89
8	Neuropeptide Y polymorphism and alcohol consumption in middleâ€aged men. American Journal of Medical Genetics Part A, 2000, 93, 117-121.	2.4	82
9	Two naturally occurring amino acid substitutions of the 5-HT2A receptor: Similar prevalence in patients with seasonal affective disorder and controls. Biological Psychiatry, 1996, 40, 1267-1272.	0.7	79
10	Right secondary somatosensory cortexâ€"a promising novel target for the treatment of drug-resistant neuropathic orofacial pain with repetitive transcranial magnetic stimulation. Pain, 2015, 156, 1276-1283.	2.0	73
11	Leucine 7 to Proline 7 Polymorphism in the Neuropeptide Y Gene Is Associated with Enhanced Carotid Atherosclerosis in Elderly Patients with Type 2 Diabetes and Control Subjects $<$ sup $>$ 1 $<$ sup $>$ 1. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 2266-2269.	1.8	71
12	Variation in the dopamine D2 receptor gene plays a key role in human pain and its modulation by transcranial magnetic stimulation. Pain, 2014, 155, 2180-2187.	2.0	70
13	Prenatal Metformin Exposure in Mice Programs the Metabolic Phenotype of the Offspring during a High Fat Diet at Adulthood. PLoS ONE, 2013, 8, e56594.	1.1	69
14	Neuropeptide Y and Y2â€receptor are involved in development of diabetic retinopathy and retinal neovascularization. Annals of Medicine, 2004, 36, 232-240.	1.5	67
15	Enhanced Exercise-Induced GH Secretion in Subjects with Pro7 Substitution in the Prepro-NPY. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 5348-5352.	1.8	62
16	Novel Delivery Systems for Improving the Clinical Use of Peptides. Pharmacological Reviews, 2015, 67, 541-561.	7.1	62
17	Pharmacokinetics of levosimendan and its active metabolite OR-1896 in rapid and slow acetylators. European Journal of Pharmaceutical Sciences, 2004, 23, 213-222.	1.9	60
18	Transgenic Mice Overexpressing Neuropeptide Y in Noradrenergic Neurons. Diabetes, 2008, 57, 1517-1525.	0.3	57

#	Article	IF	CITATIONS
19	Identification of New Sequence Variants in the Leptin Gene. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 3239-3242.	1.8	54
20	Leucine 7 to Proline 7 Polymorphism in the Preproneuropeptide Y Is Associated with Birth Weight and Serum Triglyceride Concentration in Preschool-Aged Children $<$ sup $>$ 1 $<$ /sup $>$. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 1455-1460.	1.8	54
21	Subchronic treatment with metformin produces anorectic effect and reduces hyperinsulinemia in genetically obese zucker rats. Life Sciences, 1992, 50, 1813-1820.	2.0	51
22	Prenatal Metformin Exposure in a Maternal High Fat Diet Mouse Model Alters the Transcriptome and Modifies the Metabolic Responses of the Offspring. PLoS ONE, 2014, 9, e115778.	1,1	49
23	Leucine 7 to Proline 7 Polymorphism in the Preproneuropeptide Y Is Associated With Proteinuria, Coronary Heart Disease, and Glycemic Control in Type 1 Diabetic Patients. Diabetes Care, 2004, 27, 503-509.	4.3	47
24	Hypothalamic neuropeptide expression after food restriction in Zucker rats: evidence of persistent neuropeptide Y gene activation. Molecular Brain Research, 1992, 16, 255-260.	2.5	46
25	Stress-Induced Hypertension and Increased Sympathetic Activity in Mice Overexpressing Neuropeptide Y in Noradrenergic Neurons. Neuroendocrinology, 2009, 89, 351-360.	1.2	40
26	Changes in Diurnal Sympathoadrenal Balance and Pituitary Hormone Secretion in Subjects with Leu7Pro Polymorphism in the Prepro-Neuropeptide Y. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 3278-3283.	1.8	37
27	Serotonin transporter binding and acquired obesity — An imaging study of monozygotic twin pairs. Physiology and Behavior, 2008, 93, 724-732.	1.0	35
28	Neuropeptide Y Overexpressing Female and Male Mice Show Divergent Metabolic but Not Gut Microbial Responses to Prenatal Metformin Exposure. PLoS ONE, 2016, 11, e0163805.	1.1	35
29	Enhanced endothelium-dependent vasodilation in subjects with Proline7 substitution in the signal peptide of neuropeptide Y. Atherosclerosis, 2003, 167, 319-326.	0.4	34
30	Anorectic effect of metformin in obese Zucker rats: lack of evidence for the involvement of neuropeptide Y. European Journal of Pharmacology, 1995, 273, 99-106.	1.7	32
31	COMT Val158Met Genotype Does Not Alter Cortical or Striatal Dopamine D2 Receptor Availability In Vivo. Molecular Imaging and Biology, 2010, 12, 192-197.	1.3	30
32	Striatal \hat{l} -4-opioid receptor availability predicts cold pressor pain threshold in healthy human subjects. Neuroscience Letters, 2012, 521, 11-14.	1.0	29
33	Association between Neurocognitive Impairment and the Short Allele of the 5-HTT Promoter Polymorphism in Depression: A Pilot Study. Psychiatry Journal, 2013, 2013, 1-6.	0.7	27
34	Hypothalamic Neurochemistry and Feeding Behavioral Responses to Clonidine, an Alpha-2-Agonist, and to Trifluoromethylphenylpiperazine, a Putative 5-Hydroxytryptamine-1B Agonist, in Genetically Obese Zucker Rats. Neuroendocrinology, 1990, 52, 503-510.	1.2	26
35	NPY L7P polymorphism and metabolic diseases. Regulatory Peptides, 2008, 149, 51-55.	1.9	26
36	Epistatic Interaction Between \hat{l}^2 2 -Adrenergic Receptor and Neuropeptide Y Genes Influences LDL-Cholesterol in Hypertension. Hypertension, 2004, 44, 689-694.	1.3	24

#	Article	IF	Citations
37	Anti-obesity effect of MPV-1743 AllI, a novel imidazoline derivative, in genetic obesity. European Journal of Pharmacology, 1997, 328, 207-215.	1.7	23
38	Obesity in transgenic female mice with constitutively elevated luteinizing hormone secretion. American Journal of Physiology - Endocrinology and Metabolism, 2003, 285, E812-E818.	1.8	23
39	The Leu7Pro Polymorphism of Neuropeptide Y is Associated with Younger Age of Onset of Type 2 Diabetes Mellitus and Increased Risk for Nephropathy in Subjects with Diabetic Retinopathy. Experimental and Clinical Endocrinology and Diabetes, 2006, 114, 147-152.	0.6	22
40	Chronic treatment with SCH 23390, a selective dopamine D-1 receptor antagonist, decreases dopamine metabolism in rat caudate nucleus. European Journal of Pharmacology, 1988, 155, 313-316.	1.7	20
41	Mitochondrial targeting signal in human neuropeptide Y gene. Biochemical and Biophysical Research Communications, 2005, 337, 633-640.	1.0	20
42	Potentiation of the antiâ€obesity effect of the selective β3â€odrenoceptor agonist BRL 35135 in obese Zucker rats by exercise. British Journal of Pharmacology, 1994, 113, 1231-1236.	2.7	19
43	The Leu7Pro polymorphism of the neuropeptide Y gene regulates free fatty acid metabolism. Metabolism: Clinical and Experimental, 2003, 52, 643-646.	1.5	18
44	Neurophysiology and genetics of burning mouth syndrome. European Journal of Pain, 2019, 23, 1153-1161.	1.4	18
45	The Leu7Pro Polymorphism of PreproNPY Is Associated with Decreased Insulin Secretion, Delayed Ghrelin Suppression, and Increased Cardiovascular Responsiveness to Norepinephrine during Oral Glucose Tolerance Test. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 3646-3652.	1.8	17
46	Nutrient Intake, Weight, and Leu7Pro Polymorphism in Prepro-Neuropeptide Y in Children. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 4664-4668.	1.8	17
47	Reduced Turnover of Dopamine and 5â€Hydroxytryptamine in Discrete Dopaminergic, Noradrenergic and Serotonergic Rat Brain Areas after Acutely Administered Medetomidine, a Selective α ₂ â€Adrenoceptor Agonist. Basic and Clinical Pharmacology and Toxicology, 1993, 72, 182-187.	0.0	16
48	Neuropeptide Y: A novel link between the neuroendocrine system and cholesterol metabolism. Annals of Medicine, 1998, 30, 508-510.	1.5	16
49	Leucine7 to proline7 polymorphism in prepro-NPY gene and femoral neck bone mineral density in postmenopausal women. Bone, 2004, 35, 589-594.	1.4	16
50	Identification of New Sequence Variants in the Leptin Gene. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 3239-3242.	1.8	16
51	Mutation screening of the 5-hydroxytryptamine7 receptor gene among Finnish alcoholics and controls. Psychiatry Research, 1998, 77, 139-145.	1.7	15
52	Cloning, characterisation and identification of several polymorphisms in the promoter region of the human I±2B-adrenergic receptor gene. Biochemical Pharmacology, 2004, 67, 469-478.	2.0	15
53	Sympathetic nervous system-targeted neuropeptide Y overexpression in mice enhances neointimal formation in response to vascular injury. Peptides, 2009, 30, 715-720.	1,2	15
54	Serotoninâ€transporterâ€linked promoter region polymorphism and serotonin transporter binding in drugâ€naÃve patients with major depression. Psychiatry and Clinical Neurosciences, 2010, 64, 387-393.	1.0	15

#	Article	IF	CITATIONS
55	Effects of ZD7114, a selective \hat{l}^2 3-adrenoceptor agonist, on neuroendocrine mechanisms controlling energy balance. European Journal of Pharmacology, 1998, 347, 265-274.	1.7	14
56	Dietary sucrose intake is related to serum leptin concentration in overweight pregnant women. European Journal of Nutrition, 2010, 49, 83-90.	1.8	14
57	Effects of repeated administration of mifepristone and 8-OH-DPAT on expression of preproneuropeptide Y mRNA in the arcuate nucleus of obese Zucker rats. Molecular Brain Research, 1991, 10, 267-272.	2.5	13
58	Chronic dexmedetomidine, a selective $\hat{l}\pm 2$ -agonist, decreases serotonin but not noradrenaline turnover in rat brainstem nuclei. European Journal of Pharmacology, 1990, 176, 151-157.	1.7	12
59	The leucine (7)-to-proline (7) polymorphism in the signal peptide of neuropeptide Y is not associated with Alzheimer's disease or the link apolipoprotein E. Neuroscience Letters, 2000, 287, 25-28.	1.0	12
60	Association of serotonin transporter promoter regulatory region polymorphism and cerebral activity to visual presentation of food. Clinical Physiology and Functional Imaging, 2008, 28, 270-276.	0.5	11
61	Effect of chronic treatment with TFMPP, a 5-HT1 receptor agonist, on food intake, weight gain, plasma insulin and neuropeptide mRNA expression in obese Zucker rats. European Journal of Pharmacology, 1993, 234, 191-198.	1.7	10
62	Differential Hypothalamic Arginine Vasopressin Response to Glucocorticoid Receptor Antagonism in Lean and Obese Zucker Rats. Neuroendocrinology, 1992, 56, 271-277.	1,2	9
63	The effect of endogenous preproneuropeptide Y leucine 7 to proline 7 polymorphism on growth and apoptosis in primary cultured HUVECs. Biological Chemistry, 2009, 390, 899-905.	1.2	9
64	Influence of Serotonin Transporter Gene Polymorphism (5-HTTLPR Polymorphism) on the Relation between Brain 5-HT Transporter Binding and Heart Rate Corrected Cardiac Repolarization Interval. PLoS ONE, 2013, 8, e50303.	1.1	8
65	Differential associations between brain 5-HT1A receptor binding and response to pain versus touch. Journal of Neural Transmission, 2009, 116, 821-830.	1.4	7
66	1-Sulfonyl-6-Piperazinyl-7-Azaindoles as potent and pseudo-selective 5-HT 6 receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 2610-2615.	1.0	6
67	Leucine 7 to Proline 7 Polymorphism of the Preproneuropeptide Y Gene is Not Associated with Restenosis after Coronary Stenting. Journal of Endovascular Therapy, 2003, 10, 566-572.	0.8	5
68	Impact of the Leu7Pro Polymorphism of preproNPY on Diurnal NPY and Hormone Secretion in Type 2 Diabetes. Experimental and Clinical Endocrinology and Diabetes, 2007, 115, 281-286.	0.6	5
69	The intracellular mobility of NPY and a putative mitochondrial form of NPY in neuronal cells. Neuroscience Letters, 2009, 450, 181-185.	1.0	5
70	a2-Adrenoceptor density in forebrain areas of Zucker rats: no effect of genetic obesity or antiglucocorticoid treatment. Brain Research, 1992, 574, 353-356.	1.1	4
71	Association of the leucine-7 to proline-7 variation in the signal sequence of neuropeptide Y with major depression. Acta Neuropsychiatrica, 2012, 24, 81-90.	1.0	4
72	Neuropeptide Y in the noradrenergic neurons induces the development of cardiometabolic diseases in a transgenic mouse model. Indian Journal of Endocrinology and Metabolism, 2012, 16, 569.	0.2	4

#	Article	IF	CITATIONS
73	The role of non-synonymous NPY gene polymorphism in the nitric oxide production in HUVECs. Biochemical and Biophysical Research Communications, 2009, 381, 587-591.	1.0	3
74	Human NPY gene variants in cardiovascular and metabolic diseases., 2006,, 247-267.		3
75	Leucine 7 to Proline 7 Polymorphism of the Preproneuropeptide Y Gene Is Not Associated With Restenosis After Coronary Stenting. Journal of Endovascular Therapy, 2003, 10, 566-572.	0.8	3
76	Tasipimidineâ€"the pharmacological profile of a novel orally active selective α2A-adrenoceptor agonist. European Journal of Pharmacology, 2022, 923, 174949.	1.7	3
77	Leucine 7â^°proline 7 polymorphism in the signal peptide of neuropeptide Y is not a risk factor for exudative age-related macular degeneration. Acta Ophthalmologica, 2006, 85, 188-191.	0.4	2
78	Fadolmidine $\hat{a}\in$ Favourable adverse effects profile for spinal analgesia suggested by in vitro and in vivo models. European Journal of Pharmacology, 2020, 882, 173296.	1.7	2
79	Effects of Chronic Celiprolol Treatment on Brown Fat, Feeding, and Drinking in fa/fa Zucker Rats. Pharmacology Biochemistry and Behavior, 2000, 65, 719-724.	1.3	1
80	Hypothalamic 5-Hydroxytryptamine Metabolism Is not Influenced by Streptozotocin-Diabetes Induced at Neonatal Age. Experimental and Clinical Endocrinology and Diabetes, 1990, 96, 328-330.	0.6	0
81	Effects of fadolmidine, an α 2 â€edrenoceptor agonist, as an adjuvant to spinal bupivacaine on antinociception and motor function in rats and dogs. Pharmacology Research and Perspectives, 2021, 9, e00830.	1.1	0